Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

医学 心肌梗塞 内科学 急性冠脉综合征 心脏病学 不利影响 人口 经皮冠状动脉介入治疗 随机化 随机对照试验 环境卫生
作者
Pieter C. Smits,Enrico Frigoli,Pascal Vranckx,Yukio Ozaki,Marie‐Claude Morice,Bernard Chevalier,Yoshinobu Onuma,Stephan Windecker,Pim A.L. Tonino,Marco Roffi,Maciej Lesiak,Felix Mahfoud,Jozef Bartúnek,David Hildick‐Smith,Antonio Colombo,Goran Stanković,Andrés Íñiguez,Carl Schultz,Ran Kornowski,Paul Jau Lueng Ong,Mirvat Alasnag,Alfredo E. Rodríguez,Valeria Paradies,Petr Kala,Saško Kedev,Amar Al Mafragi,Willem Dewilde,Dik Heg,Marco Valgimigli
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:80 (13): 1220-1237 被引量:20
标识
DOI:10.1016/j.jacc.2022.07.016
摘要

The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear.The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction.In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding.NACE and MACCE did not differ with abbreviated vs nonabbreviated APT regimens in patients with an acute or recent myocardial infarction (n = 1,780; HR: 0.83; 95% CI: 0.61-1.12 and HR: 0.86; 95% CI: 0.62-1.19, respectively) or without an acute or recent myocardial infarction (n = 2,799; HR: 1.03; 95% CI: 0.77-1.38 and HR: 1.13; 95% CI: 0.80-1.59; Pinteraction = 0.31 and 0.25, respectively). Bleeding Academic Research Consortium 2, 3, or 5 bleeding was significantly reduced in patients with or without an acute or recent myocardial infarction (HR: 0.65; 95% CI: 0.46-0.91 and HR: 0.71; 95% CI: 0.54-0.92; Pinteraction = 0.72) with abbreviated APT.A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Owen应助ning采纳,获得10
刚刚
1秒前
1秒前
林深完成签到,获得积分10
1秒前
周艳鸿发布了新的文献求助10
1秒前
hhjj完成签到 ,获得积分10
2秒前
2秒前
3秒前
3秒前
Ado发布了新的文献求助10
3秒前
3秒前
科研通AI6.3应助max采纳,获得10
5秒前
5秒前
6秒前
Hello应助XXX采纳,获得10
6秒前
平平完成签到,获得积分10
6秒前
镜中永恒完成签到,获得积分10
7秒前
ruochenzu发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
11132发布了新的文献求助30
7秒前
小磊完成签到,获得积分10
7秒前
芝士学豹发布了新的文献求助10
7秒前
asteria发布了新的文献求助10
7秒前
star发布了新的文献求助10
7秒前
uki发布了新的文献求助10
8秒前
舒师傅发布了新的文献求助10
8秒前
8秒前
8秒前
简单的琦发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
dllz发布了新的文献求助10
10秒前
10秒前
小磊发布了新的文献求助10
11秒前
11秒前
11秒前
小满发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1500
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Quality by Design - An Indispensable Approach to Accelerate Biopharmaceutical Product Development 800
Pulse width control of a 3-phase inverter with non sinusoidal phase voltages 777
The Cambridge Handbook of Second Language Acquisition (2nd)[第二版] 666
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6401438
求助须知:如何正确求助?哪些是违规求助? 8218640
关于积分的说明 17417283
捐赠科研通 5454189
什么是DOI,文献DOI怎么找? 2882471
邀请新用户注册赠送积分活动 1859050
关于科研通互助平台的介绍 1700744